Morgan Stanley analyst Jefferson Harralson reinstates Exelixis (NASDAQ:EXEL) with a Equal-Weight and announces $21 price target.
Morgan Stanley announces Exelixis (NASDAQ:EXEL) $21 price target Read Post »
Oppenheimer analyst Jay Olson reiterates Exelixis (NASDAQ:EXEL) with a Outperform and maintains $25 price target.
Oppenheimer maintains Exelixis (NASDAQ:EXEL) $25 price target Read Post »
GE HealthCare Technologies (NASDAQ:GEHC) reported Q2 adjusted earnings of $0.92 per diluted share, down from $1.15 a year earlier. Analysts polled by Capital IQ expected $0.87. Revenue for the quarter ended June 30 was $4.82 billion, compared with $4.48 billion a year ago. Analysts surveyed by Capital IQ expected $4.79 billion. The company said it expects full-year 2023 adjusted earnings of $3.70 to $3.85 per diluted share, compared with $3.60 to $3.75 anticipated previously. Analysts polled by Capital IQ expect $3.74.
GE HealthCare (NASDAQ:GEHC) Q2 Adjusted Earnings Fall, Revenue Rises Read Post »
Morgan Stanley Adjusts GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $78 From $76, Keeps Equalweight Rating.
Morgan Stanley Adjusts GE HealthCare (NASDAQ:GEHC) Price Target to $78 From $76 Read Post »
Bank of America Securities analyst Craig Bijou initiates coverage on GE HealthCare Techs (NASDAQ:GEHC) with a Neutral rating and announces Price Target of $82.
Bank of America announces GE HealthCare Techs (NASDAQ:GEHC) Price Target of $82 Read Post »
AbbVie (NYSE:ABBV) reported Q2 adjusted earnings of $2.91 per diluted share, down from $3.37 a year earlier. Analysts polled by Capital IQ expected $2.81. Net revenue for the quarter ended June 30 was $13.87 billion, down from $14.58 billion a year earlier. Analysts surveyed by Capital IQ expected $13.52 billion. The company said it is raising its full-year 2023 adjusted earnings guidance to $10.90 to $11.10 per diluted share from $10.57 to $10.97. Analysts polled by Capital IQ expect adjusted EPS of $10.89.
AbbVie (NYSE:ABBV) Q2 Adjusted Earnings, Net Revenue Drop Read Post »
Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $163 to $170.
Piper Sandler raises AbbVie (NYSE:ABBV) price target from $163 to $170 Read Post »
Citigroup analyst Andrew Baum maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $360 to $525.
Citigroup raises Eli Lilly (NYSE:LLY) price target from $360 to $525 Read Post »
UBS Adjusts Eli Lilly (NYSE:LLY) Price Target to $526 From $498, Maintains Buy Rating.
UBS Adjusts Eli Lilly (NYSE:LLY) Price Target to $526 From $498 Read Post »
JPMorgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $475 to $510.
JPMorgan raises Eli Lilly (NYSE:LLY) price target from $475 to $510 Read Post »
Boston Scientific (NYSE:BSX) reported Q2 adjusted earnings of $0.53 per share, up from $0.44 a year earlier. Analysts polled by Capital IQ expected $0.49. Net sales for the quarter ended June 30 were $3.60 billion, compared with $3.24 billion a year earlier. Analysts surveyed by Capital IQ expected $3.50 billion. For Q3, the medical technology company said it expects adjusted EPS of $0.46 to $0.48. Analysts surveyed by Capital IQ project $0.48. The company expects net sales for the quarter to grow from 8.5% to 10.5% compared with a year earlier. For 2023, the company said it now expects adjusted EPS of $1.96 to $2, from the prior outlook of $1.90 to $1.96 Analysts polled by Capital IQ expect $1.96.The company also raised its net sales growth outlook for the year to an 11% to 12% increase, from its previously announced range of 8.5% to 11%.
Boston Scientific (NYSE:BSX) Q2 Adjusted Earnings, Sales Rise Read Post »
Needham analyst Mike Matson maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $57 to $61.
Needham raises Boston Scientific (NYSE:BSX) price target from $57 to $61 Read Post »